Humanistic, Utilization, and Cost Outcomes Associated With the Use of Botulinum Toxin for Treatment of Refractory Migraine Headaches in a Managed Care Organization

Abstract

BACKGROUND: Few patients with migraine syndrome receive treatment with preventive medication regimens, and some of these patients fail to gain adequate migraine relief. Botulinum toxin has been suggested to be effective in the treatment of migraine for a select population. An integrated health system created a medical policy and a supporting preauthorization form that permits coverage of botulinum toxin for the off-label treatment of migraine for patients who (1) fail at least 3 drug classes for acute treatment, (2) fail at least 4 different preventive medication classes, and (3) receive consultation from a neurologist.OBJECTIVES: To (1) evaluate the impact of botulinum toxin therapy on quality-of-life (QOL) measures evaluated by direct member survey results, and (2) assess the use and cost of migraine-related medications and overall medical and pharmacy services pre-and post-botulinum toxin therapy. METHODS:The study was a retrospective analysis of administrative claims data from a 500,000-member integrated health system for the time period A survey was sent to the identified patients (N = 54) to assess 6 QOL measures associated with the use of botulinum toxin. Self-reported symptomatic improvement was assessed using a 5-point Likert scale for 6 questions regarding headache severity, headache frequency, use of rescue medications, productivity/absenteeism, recreational activities, and life enjoyment. For the subset of patients (n = 32) who maintained health plan eligibility from 18 months before through 18 months after the first botulinum toxin therapy claim (index date), medical and pharmacy claims data were used to assess the utilization and cost of specific medications and overall pharmacy and medical costs for the 18-month pre-index and post-index periods. Cost was defined as allowed charge, which is the sum of plan cost and member cost. RESULTS: Of 54 surveys sent to all patients identified as having used botulinum toxin for the treatment of migraine from January 1, 2003, to October 31, 2006, 34 surveys were returned (63%). Almost 3 of 4 respondents (73%) reported moderate or better improvement in overall migraine or headache QOL measures, and 27% reported little or no improvement. For the 32 patients with continuous eligibility for the total observation period of 36 months, the average migraine-related pharmacy utilization, excluding botulinum toxin, increased by 50.5%, from 1.84 claims per patient per month (PPPM) in the 18-month pre-index period to 2.77 claims PPPM in the 18-month post-index period (P = 0.011) and by 59.5% by mean days supply (42.58 days to 67.93, P = 0.008). Total migraine-related pharmacy cost increased by 80.9%, from $142.08 PPPM to $256.97 PPPM (P = 0.013). Acute-treatment migraine-related pharmacy utilization increased from 1.23 claims PPPM to 1.92 claims PPPM (P = 0.004). There was no significant change in either the number of claims for migraine prophylaxis medications (0.61 PPPM to 0.85 PPPM, P = 0.121) or the use of hospital emergency room services related to migraine or...

Influência de tratamentos para enxaqueca na qualidade de vida: revisão integrativa de literatura

“…Em outro estudo, foi demonstrado que a Toxina botulínica trouxe uma significante redução de episódios de enxaqueca e de dias com enxaqueca, além de melhora da qualidade de vida, se comparada ao placebo (30) . O uso de injeções de toxina botulínica no manejo da enxaqueca em pacientes que falharam com outras terapias também foi associado a uma melhora na qualidade de vida na maioria desses pacientes (28) .…”

“…Nos artigos elegidos, observou-se a efetividade do Topiramato (antiepilético e anticonvulsivante) (18)(19)(20)(21)(22)(23)(24)(25) , do Ácido Valpróico (antiepilético e anticonvulsivante) (18,26) dos β bloqueadores: Nebivolol (27) , Propanolol (18) , Metoprolol (18,27) e Nadolol (21) , dos neurolépticos (26) , do antidepressivo tricíclico Amitriptilina (22,26) , da Toxina botulínica (relaxante muscular e efeito antinocicepção) (25,(28)(29)(30) , dos bloqueadores de canal de cálcio Verapamil (26) e Flunarizina (18,26) , do Mesilato de Diidroergotamina (vasoconstritor) (31) , dos Inibidores da Recaptação Seletiva de Serotonina (IRSS) (18) , do Pizotifeno (anti-histamínico e antagonista da serotonina) (18) , dos antiinflamatórios não-esteroides (AINE) (18) e do Lisinopril (inibidor de angiotensina) (32) .…”

“…Estas consistem em uma linha com escores que variam de 0 ("extremamente ruim) a 10 ("muito bom"), sendo que o paciente deveria avaliar sua qualidade de vida se posicionando em algum ponto desta escala. Nos demais artigos foram utilizados instrumentos não validados e escala Likert, além de um artigo em que foi utilizado um instrumento alemão de avaliação de qualidade de vida, e outro em que foi usada a Headache Pain Specific Quality of Life measure (28,30,33,37,38) .…”

Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study

“…However, BTA has been considered as a relatively expensive treatment for chronic diseases. Previous studies which investigated the cost of BTA injections [1,3,8,9,13,14,[16][17][18]21] focused on particular indications, and no effort was made to calculate the daily cost of treatment, taking into account the duration of BTA injection efficacy. In clinical practice, the latter is conditioned by the subjective improvement experienced by patients themselves.…”

Botox, Migraine, and the American Academy of Neurology: An Antidote to Anecdote

“…12 Although the drug was not approved by the U.S. Food and Drug Administration (FDA) for this indication, the use of the botulinum toxin as a migraine treatment sounded promising based on the literature available at the time of the health plan's decision to cover the drug in 2003. Using a prior authorization policy, the health plan restricted treatment of migraine with botulinum toxin to patients who (1) failed at least 3 different acute treatment therapy classes, (2) failed at least 4 different preventive medication classes, and (3) received consultation from a neurologist.…”